From "Price Battle" to "Value Reconstruction": The 12th Batch of National Drug Procurement from the Perspective of Intelligent High end Equipment

Aug 18,2026

Source:

Internet

When the 12th batch of national drug procurement came to an end with "327 companies and 521 products selected", the outside world focused more on price reductions and the list of companies. From the perspective of intelligent high-end equipment, this is not a simple "price war", but a landmark event in the evolution of China's pharmaceutical supply chain towards a modern industrial system driven by data, precise regulation, and quality priority. The precision manufacturing capability and digital control system represented by intelligent equipment are becoming the implicit "technical sieve" behind the centralized procurement rules.

From "Price Battle" to "Value Reconstruction": The 12th Batch of National Drug Procurement from the Perspective of Intelligent High end Equipment

1、 Data Intelligence: From "Experience Quotation" to "Algorithm Game"
The most significant feature of this round of centralized procurement is the increase in rule complexity, which introduces mechanisms such as "standard deviation anchor point" and "abnormally low price circuit breaker". This requires companies to make dynamic decisions based on multidimensional data within a few hours. In this scenario, the quotation of enterprises is no longer manually calculated, but relies on AI assisted decision-making systems and supply chain digital twin platforms for deduction. Enterprises with advanced intelligent manufacturing capabilities can access massive data such as workshop energy consumption, batch yield, logistics and warehousing costs in real-time through MES (Manufacturing Execution System) and ERP (Enterprise Resource Planning) systems, and accurately calculate the "economic safety line" through algorithm models. This marks the shift of centralized procurement competition from "daring game" to the competition of industrial data assets, and the cost transparency of intelligent production lines has become the core moat for enterprises.

2、 Quality traceability: High end equipment ensures' clinical equivalence '
This centralized procurement clearly states "stabilizing clinical practice and ensuring quality", and opens up a "revival channel" for reference preparations and mainstream generic drugs. The confidence behind it comes from the widely deployed Continuous Manufacturing and Process Analysis (PAT) technology by leading domestic pharmaceutical companies. For example, selected large-scale enterprises such as Qilu and Kelun commonly use fully enclosed automatic feeding systems and high-precision online detection equipment in their production lines. These intelligent devices ensure high consistency between generic drugs and reference formulations in key indicators such as impurity spectra and dissolution curves. The requirement of "not downgrading or changing packaging" in the centralized procurement rules is essentially a mandatory endorsement of the process stability maintained by high-end equipment. Without a digital quality traceability system, enterprises cannot meet the strict requirements of centralized procurement for full lifecycle compliance.

3、 Supply Chain Resilience: Intelligent Logistics Cracking the 'Last Mile' at the Grassroots Level
This round of centralized procurement encourages medical consortia to uniformly report quantities and lift regional supply restrictions, targeting the pain points of accessibility to primary level medication. This relies on the support of the smart supply chain hub. High end equipment not only refers to production lines, but also includes AGV (Automated Guided Vehicle) intelligent warehousing, temperature control sensing cloud platforms, and demand forecasting systems based on big data. By building black light factories and intelligent logistics centers, top enterprises can respond to scattered orders nationwide with extremely low marginal costs. It is precisely the supply elasticity brought by this intelligence that makes the medical insurance bureau dare to relax grassroots assessments and allow flexible selection of selected brands, because the intelligent system can ensure that even orders from remote areas can be efficiently fulfilled.

4、 New paradigm of anti involution: replacing "price impulse" with "manufacturing intelligence"
The establishment of the rule of "abnormally low prices without quantity" is essentially the expulsion of low-end production capacity lacking technological content. From the perspective of high-end equipment, the space for simply compressing raw material costs is approaching its limit. A truly competitive enterprise relies on the energy consumption reduction brought by automated production lines, the equipment utilization improvement brought by intelligent scheduling, and the zero defect yield brought by AI visual inspection. Therefore, the results of this centralized procurement are not simply a "price drop", but a public ranking of industrial manufacturing intelligence (MIQ) - those enterprises that continue to invest in digitization and intelligence have received biased reporting, which is essentially a value reward for advanced productivity from the medical insurance payment system.

The late night end of the 12th batch of centralized procurement reflects the deep logic of China's pharmaceutical industry transformation: the future competition for drugs will be the competition between sensor accuracy in the workshop and cloud data flow speed. Intelligent high-end equipment is no longer just a tool for cost reduction and efficiency improvement, but also a basic entry threshold and strategic pricing weapon for participating in national medical insurance negotiations. When digital twins meet angels in white, Chinese patients not only receive price dividends, but also a new era defined by precision manufacturing and controllable quality.

The previous one

None

Next one

Only one company has released its Environmental, Social, and Governance (ESG) report for the year 2025